Daicel establishes a new company dedicated to medical related business

Daicel establishes a new company dedicated to medical related business

Oct. 13, 2023

On October 2nd, Daicel Corporation (Chief: Kita-ku, Osaka, President: Yoshimi Ogawa, hereinafter “Daicel”) has established a new company: Daicel Medical Ltd., specializing in the medical business. Daicel established the Life Sciences SBU on April 1st, 2023, and has been integrating and promoting the life science – related and medical-related businesses. In order to accelerate the expansion of the medical-related business in Life Sciences SBU, Daicel Medical Ltd. has been established to gather high quality and specialized human resources for medical devices, and meet the requirements from the customers.

<Company Profile>
Company Name：Daicel Medical Ltd.
Location：JR East Building, 2-18-1 Konan, Minato-ku, Tokyo
Capital：100 Million JPY (At time of establishment)
President：Noriaki Ito
Establishment date：October 2nd, 2023
Business Area：Design, development, manufacture, sales, import/export, support of medical devices, etc.



[Contact Information]
Daicel Investor Relations and Corporate Communications
public_relations2@jp.daicel.com

Daicel Group Invests in PharmaJet

Daicel Group Invests in PharmaJet

Oct. 13, 2023

Daicel Group Invests in PharmaJet, Continuing their Movement into the Medical Device Market

Tokyo, Japan (October 13, 2023) – Daicel Corporation (Chief: Kita-ku, Osaka, President: Yoshimi Ogawa, hereinafter “Daicel”) is pleased to announce that it has made a strategic investment in PharmaJet®, the global leader in needle-free technology. This investment comes at the same time that Daicel announces the establishment of a new company, Daicel Medical Ltd., and reinforces Daicel’s commitment to growth in this critical area of healthcare.

PharmaJet of Golden, Colorado (USA) was founded in 2005 with the strategic intent to develop a technology that enables greater access to life saving pharmaceuticals and vaccines globally. They now have a commercially scaled technology that enhances the performance of nucleic acid vaccines and therapeutics, as well as optimizes the delivery of current vaccine technologies.

PharmaJet has provided tens of millions of needle-free syringes for vaccination programs globally and has established over 80 global pharmaceutical partnerships.

“I am very pleased with our investment in PharmaJet, and our association with this excellent company. This strategic initiative continues our commitment to expand in the Life Sciences area in general, and specifically the Medical Devices industry. I think this will be the first of many such activities as we continue to build Daicel’s Life Sciences SBU.” stated Yoshimi Ogawa, President of Daicel Corporation.

“We are very pleased with the investment and confidence shown by Daicel” stated Chris Cappello, President and CEO of PharmaJet “The additional investment will allow us to continue to grow our business and focus on partnerships that bring life saving technologies to the market.”

About Daicel Corporation
Daicel is a diversified chemical company that has its roots in celluloid manufacturing and has accumulated unique technologies such as organic synthetic chemistry, polymer chemistry, cellulose chemistry, and pyrotechnic engineering for more than 100 years, and continues to expand its business in Japan and around the world.
Our basic philosophy is to be a company that “makes lives better through co-creating value”., Daicel provides materials that benefit people and society in a wide range of business fields, with the keywords of “health, safety and security”, “convenience and comfort”, and “environment”.
We are currently developing a new pyro-drive jet injector by applying the pyrotechnic engineering technology we have gained through our development of gas generators for automobile airbags.
For more information visit https://www.daicel.com/

About PharmaJet
The PharmaJet vision is to enable greater access to life-saving vaccines and pharmaceuticals globally. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs.
For more information visit https://pharmajet.com.

Daicel Address and contact info
JR Shinagawa East bldg., 2-18-1, Konan, Minato-ku, Tokyo 108-8230, Japan
Email : actranza@jp.daicel.com
https://www.daicel.com/


PharmaJet address and contact info

400 Corporate Circle, Suite N
Golden, Colorado, USA 80401
Tel: +1 888-900-4321
Email : pr@pharmajet.com
www.pharmajet.com

Daicel Chiral Technologies Announces the Availability of CHIRALPAK® IM-3

For Immediate Release

Daicel Chiral Technologies Announces the Availability of CHIRALPAK® IM-3

West Chester, PA (April 18, 2023) – Daicel Chiral Technologies is excited to announce the availability of CHIRALPAK® IM-3, the 3µm equivalent of 5µm CHIRALPAK® IM, which was previously made available in November of 2022. This new immobilized selector offers increased robustness over traditional coated technology, expanding the range of mobile phase combinations available for method development. The smaller 3µm particle size is specifically optimized for analytical and SFC applications, and provides improved resolution and peak shape. CHIRALPAK® IM is available now in 3 and 5-micron particle sizes, with 10 and 20-micron available soon.

###

About Daicel Chiral Technologies

Chiral Technologies, Inc., d/b/a Daicel Chiral Technologies, is the global leader in enantioselective chromatography serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers. The company also provides analytical method development and custom separation services. The North and Latin American markets are served through Daicel Chiral Technologies (West Chester, Pa.), the European market through Daicel Chiral Technologies Europe SAS (Illkirch, France), and the Asian market through Daicel Chiral Technologies India and Daicel Chiral Technologies China, all wholly owned subsidiaries of Daicel Corporation.

Learn more at www.chiraltech.com 

DAICEL CHIRAL TECHNOLOGIES

1475 Dunwoody Drive, Suite 310

West Chester, PA 19380 USA

(610) 594-2100

(800) 6-CHIRAL

Lorraine Evangelista, Manager, Marketing and Sales Services

chiral@cti.daicel.com

www.chiraltech.com

Daicel Chiral Technologies Announces the Launch of CHIRALPAK® IM

For Immediate Release

Daicel Chiral Technologies Announces the Launch of CHIRALPAK® IM

West Chester, PA (November 1, 2022) – Daicel Chiral Technologies introduces CHIRALPAK® IM. This new selector Cellulose 3 chloro 4 methyl phenyl carbamate is the immobilized version of CHIRALCEL® OZ. This cellulose-based immobilized chiral selector is designed for HPLC and SFC to improve the resolution and selectivity for challenging separations. The increased robustness from the immobilization process allows CHIRALPAK® IM to withstand a wider range of mobile phase combinations, which can enhance separations already achieved using CHIRALCEL® OZ.  CHIRALPAK IM is available in 5-micron particle size, with other sizes coming soon!

###

About Daicel Chiral Technologies

Chiral Technologies, Inc., d/b/a Daicel Chiral Technologies, is the global leader in enantioselective chromatography serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers. The company also provides analytical method development and custom separation services. The North and Latin American markets are served through Daicel Chiral Technologies (West Chester, Pa.), the European market through Daicel Chiral Technologies Europe SAS (Illkirch, France), and the Asian market through Daicel Chiral Technologies India and Daicel Chiral Technologies China, all wholly owned subsidiaries of Daicel Corporation.

Learn more at www.chiraltech.com 

DAICEL CHIRAL TECHNOLOGIES

1475 Dunwoody Drive, Suite 310

West Chester, PA 19380 USA

(610) 594-2100

(800) 6-CHIRAL

Lorraine Evangelista, Manager, Marketing and Sales Services

chiral@cti.daicel.com

www.chiraltech.com

Daicel Chiral Technologies Announces the Launch of CHIRALPAK® IK

For Immediate Release

Daicel Chiral Technologies Announces the Launch of CHIRALPAK® IK

West Chester, PA (November 22, 2021) —Daicel Chiral Technologies today announced the introduction of CHIRALPAK® IK, adding new selectivity capabilities to the Daicel portfolio.

This new immobilized selector builds on the success of CHIRALPAK IG, one of the most effective chiral chromatography phases used in laboratories worldwide. CHIRALPAK IK applies the same chemical derivatization as CHIRALPAK IG, but using a cellulose polymer rather than an amylose one. “CHIRALPAK IK promises to add new separations of molecules that can be analyzed with Daicel’s series of Immobilized columns,” said Joseph M. Barendt, Ph.D., President of Daicel Chiral Technologies.

In laboratory testing, CHIRALPAK IK adds new separations and enhances some separations already achieved using IG and other selectors. Beginning in November 2021, CHIRALPAK IK will be available in 5-micron particle size, with other sizes coming shortly.

To learn more about CHIRALPAK IK and our new products available CLICK HERE.

###

About Daicel Chiral Technologies

Chiral Technologies, Inc., d/b/a Daicel Chiral Technologies, is the global leader in enantioselective chromatography serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers. The company also provides analytical method development and custom separation services. The North and Latin American markets are served through Daicel Chiral Technologies (West Chester, Pa.), the European market through Daicel Chiral Technologies Europe SAS (Illkirch, France), and the Asian market through Daicel Chiral Technologies India and Daicel Chiral Technologies China, all wholly owned subsidiaries of Daicel Corporation.

Learn more at www.chiraltech.com and www.daicelchiraltech.cn.

DAICEL CHIRAL TECHNOLOGIES

1475 Dunwoody Drive, Suite 310

West Chester, PA 19380 USA

(610) 594-2100

(800) 6-CHIRAL

Lorraine Evangelista, Manager, Marketing and Sales Services

chiral@cti.daicel.com

www.chiraltech.com

Pilar Franco, Ph.D. Promoted to President of Daicel Chiral Technologies Europe

For Immediate Release

Pilar Franco, Ph.D. Promoted to President of Daicel Chiral Technologies Europe

Illkirch, France (Oct 1, 2021) – Daicel Chiral Technologies Europe is pleased to announce the promotion of Pilar Franco, Ph.D., to the position of President.

Dr. Franco has been with Chiral Technologies for 19 years, first as Product Manager, then Technical Manager, and recently in New Business Development.

Dr. Franco accepted this position upon the recent retirement of former president, Dieter Heckmann who joined the company in 1997.  In her new role, Pilar will continue to function as Manager Technical Operations and key technical expert in chiral chromatography whilst also assuming the activities of President.

Dr. Franco earned her Ph.D. in Pharmacy from the University of Barcelona, studying the preparation and use of polysaccharide derivatives as chiral stationary phases for HPLC. As a Marie Curie Fellow from the European Commission, she also performed postdoctoral work on chiral separations with Dr. W. Lindner at the University of Vienna.

###

About Daicel Chiral Technologies

Daicel Chiral Technologies is the global leader in enantioselective chromatography, serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers. The company also provides analytical method development and custom separation services. The North and Latin American markets are served through Daicel Chiral Technologies (West Chester, Pa.), the European market through Daicel Chiral Technologies Europe (Illkirch, France), and the Asian market through Daicel Chiral Technologies India and Daicel Chiral Technologies China, all wholly owned subsidiaries of Daicel Corporation.  Learn more at www.chiraltech.com and www.daicelchiraltech.cn.

Daicel Chiral Technologies Europe
Parc d’Innovation – 160, Bd Gonthier d’Andernach – CS 80140
67404 Illkirch Cedex, France

00 33 (0)3 88 79 52 00

cte@cte.daicel.com

www.chiraltech.com

Contact: Lorraine Evangelista, Manager, Marketing and Sales Services

chiral@cti.daicel.com

Daicel Chiral Technologies assists in the Separation of Several Minor Cannabinoids via Chiral HPLC

West Chester, PA (July 19, 2021) – Daicel Chiral Technologies offers high performance liquid chromatography (HPLC) application development report, to assist in the separation and identification of several cannabinoids found in commercially available cannabis products.

Published in the Cannabis Sciences and Technology Read More

To read the online version of this publication, which includes all noted chromatograms, click here www.cannabissciencetech.com/view/the-separation-of-several-minor-cannabinoids-via-chiral-hplc

Searchable Index Buttons

a:7:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:12:”options_page”;s:8:”operator”;s:2:”==”;s:5:”value”;s:18:”acf-options-footer”;}}}s:8:”position”;s:6:”normal”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;}

Digital Product List Table

a:8:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:9:”post_type”;s:8:”operator”;s:2:”==”;s:5:”value”;s:15:”digital_product”;}}}s:8:”position”;s:6:”normal”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;s:12:”show_in_rest”;i:0;}

Daicel Chiral Technologies Establishes New Chiral Separations Facility

For Immediate Release

Daicel Chiral Technologies Establishes New Chiral Separations Facility

West Chester, PA (July 8, 2021) —Daicel Chiral Technologies today announced the opening of its new preparative chiral separations facility located in Ann Arbor, MI.

To bolster and reinforce our commitment to excellence in the field of chiral separations Daicel Chiral Technologies is proud to announce the opening of its new lab facilities, located in Ann Arbor, MI, for its preparative chiral separations services. This new facility is capable of handling small to large-scale preparative separations projects, and seamlessly interfaces with Daicel’s global network of separations facilities in France, China, India, and Japan.

Daicel Chiral Technologies is also proud to announce the hiring of its newest employee, Chad Simpson, as its HPLC Chemist, to oversee the preparative separations at the new facility. Prior to joining us at Daicel Chiral Technologies, Simpson was a Process Development Chemist with CordenPharma in Boulder, Colorado.  At Corden, he handled sample prep and analysis, instrument maintenance, reporting and customer presentations. Prior to Corden, Chad progressed through several roles at Zoetis, Inc. in Chicago Heights, Illinois. He has a great deal of experience in HPLC and is proficient at maintaining and troubleshooting equipment.

Daicel Chiral Technologies has always been at the forefront in the field of polysaccharide-based chiral separations. The opening of a new facility dedicated to these efforts reaffirms our commitment to the present and future of this technology, and ensures our high standard of quality and service is continuously met well into the future” said Dr. Weston Umstead, Technology and Business Development Manager, Daicel Chiral Technologies.

###

About Daicel Chiral Technologies

Chiral Technologies, Inc., d/b/a Daicel Chiral Technologies, is the global leader in enantioselective chromatography, serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers. The company also provides analytical method development and custom separation services. The North and Latin American markets are served through

Daicel Chiral Technologies (West Chester, Pa.), the European market through Daicel Chiral Technologies Europe SAS (Illkirch, France), and the Asian market through Daicel Chiral Technologies India and Daicel Chiral Technologies China, all wholly owned subsidiaries of Daicel Corporation.  Learn more at www.chiraltech.com and www.daicelchiraltech.cn.

DAICEL CHIRAL TECHNOLOGIES

1475 Dunwoody Drive, Suite 310

West Chester, PA 19380 USA

(610) 594-2100

(800) 6-CHIRAL

Lorraine Evangelista, Manager, Marketing and Sales Services

chiral@cti.daicel.com

www.chiraltech.com